Finasteride Tablet, Film Coated
Product Images NDC 76420-154

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 76420-154). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Asclemed Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)
FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)
This figure shows the percentage of patients who had surgery for benign prostatic hyperplasia (BPH) including transurethral resection of the prostate (TURP) over a 48-month observation period. The data compares the use of finasteride versus placebo. The x-axis of the graph represents the observation time in months and the y-axis represents the percentage of patients who underwent surgery for BPH. The line for finasteride is consistently below that of the placebo, indicating a lower percentage of patients who underwent surgery in the finasteride group. The graph also includes information on the number of events and patients at risk for each group.*
FDA Label Image

Figure 3 (Finasteride Fig3)

Figure 3 (Finasteride Fig3)
The figure 3 shows the percentage of patients developed acute urinary retention due to spontaneous and precipitated causes. However, no explanation or context is available to interpret the data accurately.*
FDA Label Image

Figure 4 (Finasteride Fig4)

Figure 4 (Finasteride Fig4)
This is a graph showing the mean percent change from baseline in prostate volume over the course of a long-term efficacy and safety study. The study tracked the progress of two groups of patients, one receiving a placebo and the other receiving finasteride. The data shows that over the course of three years, patients receiving finasteride experienced a consistently greater reduction in prostate volume compared to those receiving a placebo. These results suggest that finasteride may be an effective treatment for patients with benign prostatic hyperplasia (BPH).*
FDA Label Image

Figure 5 (Finasteride Fig5)

Figure 5 (Finasteride Fig5)
FDA Label Image

Label (Finasteride Fig6)

Label (Finasteride Fig6)
This is a list of packages of Finasteride Tablets, USP 5mg, with various quantities and lot and batch numbers. The drug is RX only and these packages are distributed by Rising Health, LLC. The CAUTION message is present, which states that federal law prohibits dispensing without prescription and to keep out of reach of children. The storage temperature of the drug is also indicated as 20-25C. The packages are produced and labeled by Enovachem.*
FDA Label Image

Chemical Structure (Finasteride Str)

Chemical Structure (Finasteride Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.